Drug Profile
HI 164
Alternative Names: HI-164N; HI-164OVLatest Information Update: 27 Aug 2019
Price :
$50
*
At a glance
- Originator Hunter Immunology
- Developer Mariposa Health Limited
- Class Haemophilus vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Chronic obstructive pulmonary disease
- Discontinued Bronchitis; Otitis media; Sinusitis
Most Recent Events
- 27 Aug 2019 HI 164 is still in phase II for Chronic obstructive pulmonary disease in Australia (Mariposa Health pipeline, August 2019)
- 24 Jul 2015 Phase-II development for Chronic obstructive pulmonary disease (prevention of exacerbation) is ongoing in Australia
- 30 Jun 2014 Mariposa Health Limited acquires Hunter Immunology